On October 21, 2019, Eton Pharmaceuticals Inc. (ETON) will know whether or not ET-202, its ready-to-use injectable formulation of phenylephrine, gets FDA approval.ET-202 is proposed for increasing blood pressure in adults with clinically significant hypotension resulting primarily from vasodilation in such settings as septic shock or anesthesia.Currently, hospitals must manually dilute phenylephrine prior to administration or purchase ready-to-use formulations from 503B compounding pharmacies for the treatment hypotension in surgical settings. Eton believes the addressable phenylephrine market for ET-202 is more than 10 million units annually.If all goes to plan, ET-202 is expected to be the first and only FDA-approved phenylephrine in a ready-to-use formulation.ETON closed Friday’s (Sep.27, 2019) trading at $6.20, down 2.05%.